Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis by Blasetti Fantauzzi, C. et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20070  | https://doi.org/10.1038/s41598-020-76952-z
www.nature.com/scientificreports
Galectin‑3 gene deletion 
results in defective adipose 
tissue maturation and impaired 
insulin sensitivity and glucose 
homeostasis
Claudia Blasetti Fantauzzi1,4, Carla Iacobini1,4, Stefano Menini1, Martina Vitale1, 
Gian Pio Sorice2, Teresa Mezza2, Saverio Cinti3, Andrea Giaccari2 & Giuseppe Pugliese1*
Adiposopathy is a pathological adipose tissue (AT) response to overfeeding characterized by reduced 
AT expandability due to impaired adipogenesis, which favors inflammation, insulin resistance (IR), 
and abnormal glucose regulation. However, it is unclear whether defective adipogenesis causes 
metabolic derangement also independently of an increased demand for fat storage. As galectin‑3 has 
been implicated in both adipocyte differentiation and glucose homeostasis, we tested this hypothesis 
in galectin‑3 knockout (Lgal3−/−) mice fed a standard chow. In vitro, Lgal3−/− adipocyte precursors 
showed impaired terminal differentiation (maturation). Two‑month‑old Lgal3−/− mice showed impaired 
AT maturation, with reduced adipocyte size and expression of adipogenic genes, but unchanged fat 
mass and no sign of adipocyte degeneration/death or ectopic fat accumulation. AT immaturity was 
associated with AT and whole‑body inflammation and IR, glucose intolerance, and hyperglycemia. 
Five‑month‑old Lgal3−/− mice exhibited a more mature AT phenotype, with no difference in insulin 
sensitivity and expression of inflammatory cytokines versus WT animals, though abnormal glucose 
homeostasis persisted and was associated with reduced β‑cell function. These data show that 
adipogenesis capacity per se affects AT function, insulin sensitivity, and glucose homeostasis 
independently of increased fat intake, accumulation and redistribution, thus uncovering a direct link 
between defective adipogenesis, IR and susceptibility to diabetes.
Abbreviations
AT  Adipose tissue
IR  Insulin resistance
PPAR  Peroxisome proliferator-activated receptor
Lgals3−/−  Galectin 3 knockout
WT  Wild-type
SVF  Stromal vascular precursor
SAT  Subcutaneous AT
Dlk1  Preadipocyte factor 1 or Delta Like Non-Canonical Notch Ligand gene
Pparg  PPARγ gene
CEBP  Ccaat-Enhancer-Binding Protein
Cebpb  CEBP β gene
Pnpla2  Adipose Triglyceride Lipase or Patatin Like Phospholipase Domain Containing 2 gene
Srebf1  Sterol Regulatory Element Binding Transcription Factor 1 gene
Acaca  Acetyl-CoA Carboxylase α gene
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Fasn  Fatty Acid Synthase gene
Adipoq  Adiponectin gene
IL  Interleukin
Il6  IL-6 gene
Ccl2  Monocyte chemoattractant protein 1 or C–C Motif Chemokine Ligand 2 gene
Ccnd1  Cyclin D1 gene
BrdU  5-Bromo-2′-deoxyuridine
VAT  Visceral AT
Cebpa  CEBP α gene
Fabp4  Fatty acid binding protein 4 gene
Lep  Leptin gene
Cdf  Adipsin or Complement Factor D gene
BAT  Brown AT
Cidea  Cell Death-Inducing DFFA-Like Effector A gene
Ppara  PPARα gene
Ucp1  Uncoupling Protein 1 gene
NEFAs  Non-esterified fatty acids
TNF  Tumor necrosis factor
Tnfa  Tumor necrosis factor -α gene
Il1b  IL-1β gene
ER  Endoplasmic reticulum
Hspa5  Heat Shock Protein Family A Member 5 gene
Ddit3  C/EBP-Homologous Protein 10 or DNA Damage Inducible Transcript 3 gene
Xbp1  Tax-Responsive Element-Binding Protein 5 or X-Box Binding Protein 1 gene
Fn1  Fibronectin 1 gene
Cola1a1  Collagen Type I Alpha 1 Chain gene
Cola4a1  Collagen Type IV Alpha 1 Chain gene
Cola6a1  Collagen Type VI Alpha 1 Chain gene
Slc2a4  Glucose Transporter Type 4 or Solute Carrier Family 2 Member 4 gene
Irs1  Insulin Receptor Substrate 1 gene
Insr  Insulin Receptor gene
IPGTT  Intraperitoneal glucose tolerance test
HOMA  Homeostasis model assessment
HOMA-IR  HOMA-insulin resistance
Cd68  Cluster of differentiation 68
HOMA-%β  HOMA-β-cell function
Actb  β-Actin gene
The ongoing epidemics of obesity and diabetes have focused attention on adipose tissue (AT)1, as fat accumula-
tion is causally related to insulin resistance (IR) and type 2  diabetes2. However, the existence of both metaboli-
cally healthy obese individuals and unhealthy insulin-resistant lean (metabolically obese)  subjects3 indicates 
that it is not just a matter of absolute quantity of fat and shifts the focus on dysfunction of AT and remodeling 
of AT depots, i.e., the so-called  adiposopathy4,5. Adiposopathy is a pathological AT response to positive caloric 
balance in susceptible individuals contributing to increased cardiometabolic risk. It is characterized by limited 
AT plasticity, i.e., reduced capacity to expand and accommodate the surplus of  energy6. Expansion of AT relies 
upon adipogenesis, the process by which pluripotent mesenchymal stem cells commit to the adipose lineage to 
become pre-adipocytes, which then differentiate into adipocytes by undergoing mitotic clonal expansion, fol-
lowed by growth arrest and terminal differentiation with acquisition of a mature phenotype, i.e., expression of 
adipocyte genes and accumulation of  triglycerides7. The overall AT capacity to store excess fat is dependent upon 
the ability of increasing both adipocyte number and size without achieving a critical cell  volume4. When this 
capacity is overwhelmed, adipocytes degenerate and die by  pyroptosis8, with consequent fibrosis and macrophage 
 infiltration9. These processes ultimately lead to ectopic fat accumulation, tissue and systemic inflammation 
and IR, and development of type 2  diabetes10,11. While the role of adiposopathy in the pathological response to 
positive caloric balance is well established, it is unclear whether impaired adipogenesis per se may affect insulin 
sensitivity and glucose homeostasis, independently of an increased demand for fat storage.
Among the factors that control adipogenesis by regulating the various steps in the commitment and differen-
tiation  programs7, there is galectin-312, a multifunctional protein involved in many physiological and pathological 
 processes13,14. In human AT, galectin-3 was found to be expressed also by  adipocytes15, where it is modulated 
during cell  differentiation16. Moreover, Baek et al. reported that galectin-3 induces nuclear translocation and acti-
vation of peroxisome proliferator-activated receptor (PPAR) γ in 3T3-L1 cells, whereas both mouse embryonic 
fibroblasts isolated from galectin 3 knockout (Lgals3−/−) mice and stably galectin-3-silenced 3T3-L1 cells show 
delayed adipogenic  differentiation17. They also found that aged (17-month-old) Lgals3−/− mice display reduced 
body weight associated with decreased epididymal AT size and expression of adipogenic and lipogenic genes 
compared with wild-type (WT)  mice17. Finally, other studies reported unchanged weight gain associated with 
either increased blood glucose levels in younger (3-to-5-month-old)18,19 or improved glucose regulation in older 
(8-month-old)20 Lgals3−/− versus WT mice.
To date, the relationship between decreased AT expression of adipogenic and lipogenic  genes17 and impaired 
glucose homeostasis associated with unchanged body  weight18,19 in Lgals3−/− mice fed a standard chow remains 
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unexplored. The aim of this study was to gain pathophysiological insights into the role of AT dysfunction due 
to defective adipogenesis in the impaired glucose regulation occurring in Lgals3−/− mice in the absence of an 
increased demand for fat storage. To this end, the Lgals3−/− mouse appears to be a suitable model for testing 
the working hypothesis that impaired adipogenesis may directly affect glucose homeostasis and contribute to 
metabolic derangement independently of environmental obesogenic or diabetogenic stimuli.
Results
In vitro studies. Adipogenic differentiation of adipocyte precursors. Adipose-derived stromal vascular frac-
tion (SVF) precursor cells were isolated from subcutaneous AT (SAT) of WT and Lgals3−/− and exposed to an 
adipogenic medium. Under these conditions, Lgals3 expression increased in SVF cells from WT mice (Fig. 1a). 
The SVF cells from Lgals3−/− mice, though replicated well in culture, showed impaired adipogenesis, maintaining 
an immature (fibroblast-like) phenotype (Fig. 1b) with negative Oil-Red-O staining even after 14 days (Fig. 1c). 
Conversely, the SVF cells from WT mice differentiated into round shaped adipocytes (Fig. 1b), filled with Oil-
Red-O positive lipid droplets (Fig. 1c). Consistently, Lgals3−/− cells showed higher Preadipocyte factor 1 or Delta 
Like Non-Canonical Notch Ligand (Dlk1) (Fig. 1d) and lower PPARγ (Pparg), but unchanged Ccaat-Enhancer-
Binding Protein (CEBP) β (Cebpb) gene expression levels (Fig. 1d), as compared with WT cells. The mRNA 
levels of the genes involved in lipid metabolism Adipose Triglyceride Lipase or Patatin Like Phospholipase Do-
main Containing 2 (Pnpla2), Sterol Regulatory Element Binding Transcription Factor 1 (Srebf1), Acetyl-CoA 
Figure 1.  In vitro adipogenic differentiation of SVF cells. Lgals3 mRNA levels from SVF cells of WT mice 
cultured in normal control (Ctr) or adipogenic (Adip) medium (a); representative images of adipogenic 
differentiation of SVF cells isolated from SAT of WT and Lgals3−/− mice, cultured in control or adipogenic 
medium for 14 days (original magnification, 10X or 20X) (b); oil-Red-O staining of WT and Lgals3−/− SVF cells 
induced to differentiation (c); qRT-PCR analysis of genes involved in adipogenesis (Dlk1, Cebpb, and Pparg) (d), 
lipid metabolism (Srebf1, Acaca, Fasn, and Pnpl + a2) (e), adipokine synthesis (Adipoq) (f), inflammation (Il6 
and Ccl2) (g), and proliferation (Ccnd1) (h); and analysis of BrdU incorporation (i) from SVF cells induced to 
differentiation of WT and Lgals3−/− mice. Values represent the mean ± SD of two independent experiments (n = 3 
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Carboxylase α (Acaca), Fatty Acid Synthase (Fasn) (Fig. 1e) and the adiponectin gene (Adipoq) (Fig. 1f) were 
also lower, whereas those of the inflammatory markers interleukin (IL)-6 (Il6) and monocyte chemoattractant 
protein 1 or C–C Motif Chemokine Ligand 2 (Ccl2) were higher (Fig. 1g) in Lgals3−/− versus WT cells. In addi-
tion, the mitotic clonal expansion following adipogenesis induction was abnormally regulated in Lgals3−/− SVF 
cells. In fact, the expression of the gene coding for the cell cycle regulator cyclin D1 (Ccnd1), which is required 
for G1/S transition and is degraded as the cell enters the S phase (Fig. 1h), and the incorporation of the prolif-
eration marker 5-bromo-2′-deoxyuridine (BrdU) (Fig. 1i) showed little or no decrease, respectively, 48 and 72 h 
after exposure to adipogenic medium in SVF cells from Lgals3−/− mice, at variance with those from wild type 
animals. In addition, baseline BrUD incorporation was higher in Lgals3−/− versus wild type SVF cells.
Lipid metabolism in mature adipocytes. To rule out the possibility that the reduced lipid accumulation detected 
in adipocytes derived from Lgals3−/− SVF cells was due impaired lipid metabolism instead of defective adipogen-
esis, Lgals3 was silenced in mature adipocytes. No differences were observed in the gene expression for lipogenic 
and lipolytic enzyme between silenced and non-silenced cells (Supplementary Fig. 2).
In vivo/ex vivo studies. The growth curve did not differ between the two genotypes throughout the study 
(Supplementary Fig. 1a), as did food intake (not shown). Conversely, fasting plasma glucose levels showed a 
trend toward an increase in Lgals3−/−Lgals3−/− versus WT mice, which became significant at 3 months of age 
(Supplementary Fig. 1b). The animals were studied at 2 and 5 months of age.
Two‑month‑old mice. AT phenotype. Lgals3−/− mice showed no change in visceral AT (VAT) or SAT 
mass compared to coeval WT mice (Fig. 2a). No obvious sign of adipocyte degeneration was observed in VAT 
from Lgals3−/− mice (Fig. 2b). Morphometric analysis revealed a significant decrease in average adipocyte size 
in VAT (Fig. 2b) and particularly in SAT (Fig. 2c) of Lgals3−/− mice. Moreover, VAT from Lgals3−/− mice showed 
a higher number and density of adipocytes as well as a change in adipocyte size distribution, with a higher fre-
quency of smaller adipocytes (Fig. 2b). Furthermore, the transcriptional levels of genes involved in adipogenesis 
(Pparg and CEBP α [Cebpa] in SAT and VAT), and lipogenesis (Srebf1 in SAT and Acaca in VAT) as well as of 
genes coding for adipokines (leptin [Lep] in SAT and VAT and Adipsin or Complement Factor D [Cdf] only in 
SAT) were reduced in Lgals3−/− versus WT mice (Table 1). Transcripts for Pparg, Srebf1, Acaca, and Fasn were 
reduced in brown AT (BAT) (Table 1). The expression levels of the “browning” genes Cell Death-Inducing DF-
FA-Like Effector A (Cidea) and PPARα (Ppara) were also lower in SAT from Lgals3−/− versus WT mice. Further-
more, the gene expression for Uncoupling Protein 1 (Ucp1) was significantly reduced in BAT of Lgals3−/− versus 
WT mice (Table 1). Circulating leptin was markedly reduced in Lgals3−/− versus WT mice, whereas adiponectin 
and non-esterified fatty acid (NEFA) levels were unchanged (Fig. 2d).
AT and systemic inflammation. The gene expression of tumor necrosis factor (TNF)-α (Tnfa) and Il6 were sig-
nificantly increased in both SAT and VAT, whereas the mRNA levels of IL-1β (Il1b) and Ccl2 were increased only 
in VAT of Lgals3−/− versus WT mice (Fig. 3a). Immunohistochemical analysis revealed a higher number of F4/80 
positive cells in VAT of Lgals3−/− animals (Fig. 3b). However, no crown-like structures or dead/dying adipocytes, 
i.e., negative for the lipid droplet coating protein perilipin-121, were observed (Supplementary Fig. 3). In sera, 
the concentration of IL-6 was significantly higher in Lgals3−/− than in WT mice (Fig. 3c), whereas TNF-α and 
IL-1β levels were below the limit of detectability in both genotypes. No difference was observed between the two 
genotypes in the VAT expression of genes coding for the endoplasmic reticulum (ER) stress markers Heat Shock 
Protein Family A Member 5 (Hspa5), C/EBP-Homologous Protein 10 or DNA Damage Inducible Transcript 
3 (Ddit3), and Tax-Responsive Element-Binding Protein 5 or X-Box Binding Protein 1 (Xbp1) (Fig. 3d). The 
mRNA levels of Collagen Type I Alpha 1 Chain (Cola1a1) and Collagen Type I Alpha 1 Chain (Cola4a1) were 
significantly increased only in BAT of Lgals3−/− versus WT mice, whereas levels of these and other genes involved 
in fibrosis (i.e., Fibronectin 1 [Fn1] and Collagen Type VI Alpha 1 Chain [Cola6a1]) were comparable between 
the two genotypes in both VAT and SAT (Table 1).
Tissue insulin sensitivity. Lgals3−/− mice showed a significant decrease in the gene expression of Glucose Trans-
porter Type 4 or Solute Carrier Family 2 Member 4 (Slc2a4) in SAT, VAT, and BAT and Insulin Receptor Sub-
strate 1 (Irs1) in SAT, as compared to WT animals (Table 1). Insulin-stimulated AKT phosphorylation and glu-
cose uptake were markedly decreased in VAT from Lgals3−/− versus WT mice (Fig. 4a-b), whereas no significant 
difference in glucose uptake was observed in skeletal muscle (Fig. 4c).
Systemic insulin sensitivity and glucose homeostasis. Lgals3−/− mice showed unchanged fasting plasma glucose 
levels with an exaggerated glycemic response to the intraperitoneal glucose tolerance test (IPGTT) (Fig. 4d) 
as well as increased insulin levels, as compared to WT mice (Fig.  4e). The homeostasis model assessment 
(HOMA)—insulin resistance (IR) index was also increased in Lgals3−/− versus wild type mice (Fig. 4f) and the 
euglycemic-hyperinsulinemic clamp confirmed the lower whole-body insulin sensitivity in the Lgals3−/− animals 
(Fig. 4g).
Five‑month‑old mice. AT phenotype. A substantial improvement in SAT and VAT maturation was ob-
served in Lgals3−/− mice, which showed similar gene expression levels of almost all markers of adipogenesis and 
lipid metabolism to those of WT mice (Table 2). However, adipocyte size remained significantly lower in both 
VAT (Fig. 5a) and SAT (Fig. 5b), and the number and density of VAT adipocytes as well as the frequency of 
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Figure 2.  AT phenotype and serum levels of adipokines and NEFAs in WT and Lgals3−/− mice aged 2 months. 
Weight of VAT and SAT (a); representative haematoxylin–eosin images of VAT (b) and SAT (c) (original 
magnification, 250X), quantification of size of adipocytes from VAT (b) and SAT (c), and number, density 
and size distribution of adipocytes from VAT (b) from WT and Lgals3−/− mice; and serum levels of leptin, 
adiponectin and NEFAs in WT and Lgals3−/− mice (d). Values represent the mean ± SD (n = 6 mice per 
genotype). White bars = WT mice; black bars = Lgals3−/− mice; *P < 0.05, **P < 0.01 or ***P < 0.001 versus WT.
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smaller cells remained significantly higher (Fig. 5a), compared to WT mice. In addition, serum concentration 
of leptin remained lower in Lgals3−/− than in WT mice, and adiponectin levels continued to be similar between 
the two genotypes (Fig. 5c).
AT and systemic inflammation. Both AT and systemic inflammation reversed almost completely in Lgals3−/−, 
with no difference in transcript levels of inflammatory cytokines versus WT animals (Fig. 5d) and serum TNF-
α, IL-1β, and IL-6 below the limit of detectability in both genotypes. However, the number of macrophages 
remained significantly higher in VAT of 5-month-old Lgals3−/− versus wild type mice, as assessed by both F4/80-
positive cell count and expression of the gene coding for Cluster of Differentiation 68 (Cd68) macrophage 
marker (Fig. 5e).
Tissue insulin sensitivity. Insulin-dependent AKT activation and glucose uptake in VAT (Fig. 6a,b) and glucose 
uptake in muscle (Fig. 6c) were similar in Lgals3−/− and WT mice.
Systemic insulin sensitivity and glucose homeostasis. Fasting plasma glucose levels were significantly higher 
(Fig.  6d) and the glucose response to the IPGTT remained abnormal (Fig.  6e) in Lgals3−/−. Insulin levels 
decreased markedly in Lgals3−/− mice and became significantly lower than in WT animals (Fig. 6f), with a signif-
icant reduction in the HOMA-β-cell function (HOMA-%β) index (Fig. 6g). The euglycemic-hyperinsulinemic 
clamp demonstrated comparable systemic insulin sensitivity in Lgals3−/− and WT mice (Fig. 6h).
Table 1.  Adipogenesis, lipid metabolism and fibrosis in adipose tissue of 2-month-old mice. Expression of 
genes involved in adipogenesis, white and brown/beige lipid metabolism, insulin signaling, and fibrosis in 
SAT, VAT and BAT from 2-month-old WT and Lgals3−/− mice. Values represent the mean ± SD (n = 7 per 
genotype). P values calculated by t-test between WT and Lgals3−/−: *P < 0.05; †P < 0.01 and ‡P < 0.001 versus the 
corresponding WT mice.
SAT VAT BAT
WT Lgals3−/− WT Lgals3−/− WT Lgals3−/−
Adipogenesis
Cebpb 0.91 ± 0.41 0.31 ± 0.16† 1.80 ± 1.48 1.77 ± 0.99 1.45 ± 0.47 0.91 ± 0.31
Pparg 0.61 ± 0.25 0.42 ± 0.29* 1.31 ± 0.68 0.96 ± 0.39* 1.03 ± 0.24 0.57 ± 0.16*
Cebpa 0.61 ± 0.24 0.27 ± 0.16* 1.04 ± 0.56 0.56 ± 0.17* 0.90 ± 0.13 0.71 ± 0.08
Lipolysis
Pnpla2 0.47 ± 0.31 0.21 ± 0.10 0.81 ± 0.62 0.64 ± 0.39 0.93 ± 0.16 0.72 ± 0.15
Lipogenesis
Srebf1 0.90 ± 0.39 0.49 ± 0.06* 1.07 ± 0.45 1.14 ± 0.32 0.93 ± 0.06 0.59 ± 0.04‡
Acaca 0.68 ± 0.39 0.63 ± 1.19 0.89 ± 0.32 0.54 ± 0.14* 1.03 ± 0.24 0.17 ± 0.04†
Fasn 0.68 ± 0.76 0.81 ± 1.31 1.09 ± 0.50 0.70 ± 0.68 0.93 ± 0.06 0.13 ± 0.04‡
Fabp4 0.54 ± 0.34 0.24 ± 0.09 0.80 ± 0.60 0.56 ± 0.25 1.03 ± 0.33 0.66 ± 0.09
Adipokines
Lep 0.42 ± 0.33 0.10 ± 0.08* 0.56 ± 0.29 0.17 ± 0.12* 0.80 ± 0.21 0.44 ± 0.26
Adipoq 0.73 ± 0.28 0.45 ± 0.19 1.22 ± 0.64 0.81 ± 0.23 1.04 ± 0.40 0.80 ± 0.20
Cfd 0.83 ± 0.46 0.33 ± 0.12* 1.40 ± 1.02 0.87 ± 0.33 1.10 ± 0.37 0.87 ± 0.12
Browning
Cidea 0.34 ± 0.37 0.08 ± 0.02* 0.87 ± 0.86 0.65 ± 0.85 0.95 ± 0.18 0.72 ± 0.19
Ppara 0.50 ± 0.36 0.13 ± 0.06* 1.59 ± 0.99 1.12 ± 0.73 1.17 ± 0.36 0.74 ± 0.25
Ucp1 N/A N/A N/A N/A 0.91 ± 0.17 0.42 ± 0.16*
Insulin signaling
Slc2a4 0.45 ± 0.38 0.06 ± 0.08* 1.35 ± 0.35 0.73 ± 0.22‡ 0.97 ± 0.04 0.31 ± 0.08‡
Insr 0.70 ± 0.30 0.47 ± 0.15 1.10 ± 0.34 1.42 ± 0.39 1.04 ± 0.17 0.87 ± 0.04
Irs1 0.84 ± 0.23 0.50 ± 0.24* 1.02 ± 0.60 0.70 ± 0.25 1.46 ± 0.94 1.12 ± 0.24
Fibrosis
Fn1 1.67 ± 1.73 0.64 ± 0.22 2.32 ± 1.72 3.65 ± 1.06 1.14 ± 0.17 0.94 ± 0.06
Cola1a1 3.32 ± 4.22 2.76 ± 2.96 1.44 ± 0.85 3.01 ± 1.75 0.92 ± 0.10 1.36 ± 0.17*
Cola4a1 0.49 ± 0.29 0.25 ± 0.10 0.84 ± 0.56 1.02 ± 0.66 0.97 ± 0.13 1.26 ± 0.01*
Cola6a1 0.58 ± 0.24 0.36 ± 0.12 1.06 ± 0.68 1.51 ± 1.28 0.98 ± 0.03 1.47 ± 0.41
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Discussion
This study indicates that, under normal feeding conditions, Lgals3 deletion results in impaired terminal adipo-
genic differentiation associated with AT dysfunction and inflammation, IR, and altered glucose regulation, in 
the absence of obvious signs of adipocyte degeneration/death and changes in both the amount and distribution 
of body fat. From a pathomechanistic point of view, our data support the concept that AT dysfunction limit-
ing tissue plasticity and fat storage capacity may derive not only by a reduced hyperplastic AT response due to 
defective recruitment and expansion of adipocyte precursors (first step of adipogenesis), but also by a failure 
of adipocytes to accumulate lipids, due to defective terminal differentiation of pre-adipocytes into fully mature 
cells (second step of adipogenesis).
Deletion of Lgals3 led to severely impaired adipogenesis in vitro. The SVF cells isolated from Lgals3−/− mice 
failed to undergo growth arrest and terminal differentiation into mature adipocytes following adipogenic induc-
tion, with consequent uninterrupted clonal expansion and impaired expression of adipocyte genes and reduced 
accumulation of triglycerides. This extreme in vitro phenotype translated into a less severe in vivo phenotype, 
characterized by delayed AT maturation and function, as shown by the reduced expression of genes involved in 
adipogenesis, browning, lipid metabolism, and endocrine function only in younger (2-month-old) Lgals3−/− mice. 
AT immaturity resulted in decreased adipocyte size and increased percentage of smaller adipocytes, pointing 
to a reduced fat storing capacity of each individual cell. However, these changes were associated with increased 
adipocyte number and density depending on a shift in the balance between proliferation/clonal expansion and 
terminal differentiation in favor of the former, occurring in the absence of galectin-3 during AT development. 
Therefore, total fat (VAT and SAT) mass was unchanged, suggesting that the overall AT capacity of accumulating 
lipids was unaffected, at least in the absence of an increased demand for fat storage. Consistently, AT immaturity 
was not associated with hypertrophy-induced adipocyte damage, increased NEFA release, and, as previously 
shown in the liver from Lgals3−/− mice fed a standard diet, fat diversion to ectopic  sites22.
Figure 3.  Tissue and systemic inflammation in WT and Lgals3−/− mice aged 2 months. qRT-PCR analysis of 
the inflammatory markers Tnfa, Il1b, Il6, and Ccl2 in SAT and VAT (a); representative immunohistochemical 
staining for F4/80 (original magnification, 400X; black arrows = macrophages), and measurement of positive cell 
number in VAT (b); serum levels of IL-6 (c); and qRT-PCR analysis of the ER stress markers Hspa5, Ddit3, and 
Xbp1 in VAT (d) in WT and Lgals3−/− mice. Values represent the mean ± SD (n = 6 mice per genotype). White 
bars = WT mice; black bars = Lgals3−/− mice; *P < 0.05, **P < 0.01 or ***P < 0.001 versus WT.
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Figure 4.  Tissue and systemic insulin sensitivity and glucose homeostasis in 2-month-old WT and Lgals3−/− 
mice. Representative Western blot analysis of phospho-AKT (p-AKT, 60 kDa) and total AKT (AKT, 60 kDa) in 
protein extracts from WT and Lgals3−/− VAT cultures stimulated with insulin and quantification of phospho-
AKT (active AKT) relative to total AKT (n = 4 per genotype) (a); measurement of glucose uptake in ex vivo 
cultures of VAT (b) and skeletal muscle (c) treated with insulin (1 µM) and 2-deoxy-D-glucose (1 mM) 
from WT or Lgals3−/− mice (n = 4 per genotype); IPGTT (n = 5 per genotype) (d); fasting insulin levels (e), 
and calculation of HOMA-IR index in WT and Lgals3−/− mice (n = 6 per genotype) (f); and euglycaemic-
hyperinsulinemic clamp in WT and Lgals3−/− mice (n = 7 per genotype) (g). Values represent the mean ± SD. 
White bars and squares, continuous line = WT mice; black bars and triangles, dashed line = Lgals3−/− mice; 
*P < 0.05, **P < 0.01 or ***P < 0.001 versus WT.
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Nevertheless, incomplete AT maturation (terminal differentiation) was associated with tissue and systemic 
inflammation and IR, ultimately leading to impaired glucose homeostasis. Inflammation was detected both 
in pre-adipocytes derived from Lgals3−/− SVF cells and Lgals3−/− mice at the AT and systemic level, consistent 
with previous findings that mesenchymal stem cells and human pre-adipocytes are the primary source of pro-
inflammatory cytokines/chemokines23–25, particularly IL-6, the levels of which dramatically decrease during 
adipogenic  differentiation23,24. Immature adipocytes from the AT may also have contributed to the increased 
plasma IL-6 levels of 2-month-old Lgals3−/− mice, as previously demonstrated in leptin-deficient obese (ob/
ob)  mice24. In parallel with the defective maturation and increased expression of IL-6, ex vivo glucose uptake 
and insulin sensitivity were reduced in AT, whereas they were unaffected in muscle, consistent with previous 
observations in Lgals3−/−  mice26. These changes at the AT level resulted in an impairment of whole-body insulin 
sensitivity and glucose homeostasis, which were associated with increased circulating levels of IL-6, in keeping 
with the findings that serum IL-6 levels are elevated in IR and metabolic  disorders27,28 and that chronic exposure 
to IL-6 produces muscle  IR29. Though whole-body IR as measured by the euglycemic-hyperinsulinemic clamp 
technique is mainly accounted for by a reduction in muscle insulin sensitivity, the unchanged NEFA levels despite 
twice-higher insulin concentrations provided indirect evidence that the AT of Lgals3−/− mice was insulin resistant 
also in vivo, consistent with the ex vivo findings.
In vivo, AT maturation was only delayed, since at 5 months of age the gene expression profile was not different 
between Lgals3−/− and coeval wild type mice. In parallel, AT and systemic inflammation and IR were no longer 
observed in 5-month-old Lgals3−/− mice, further supporting the relationship of these changes with the impaired 
AT maturation observed in younger animals. Conversely, the number of macrophages continued to be elevated 
in the VAT of Lgals3−/− mice, a finding possibly related to the lack of the specific regulatory functions of Lgals3 
in macrophage  homeostasis30,31. In addition, the comparable increase in AT macrophages from Lgals3−/− versus 
wild type animals at 2 and 5 months of age further supports the concept that immature adipocytes are the main 
source of the increased cytokine levels observed in 2-month-old Lgals3−/− mice. Despite maturation of adipocytes, 
Table 2.  Adipogenesis, lipid metabolism and fibrosis in adipose tissue of 5-month-old mice. Expression of 
genes involved in adipogenesis, white and brown/beige lipid metabolism, insulin signaling, and fibrosis in 
SAT, VAT and BAT from 5-month-old WT and Lgals3−/− mice. Values represent the mean ± SD (n = 7 per 
genotype). P values calculated by t-test between WT and Lgals3−/−: *P < 0.05; †P < 0.01 and ‡P < 0.001 versus the 
corresponding WT mice.
SAT VAT BAT
WT Lgals3−/− WT Lgals3−/− WT Lgals3−/−
Adipogenesis
Cebpb 1.31 ± 1.63 0.80 ± 0.58 1.34 ± 1.02 0.78 ± 0.47 0.84 ± 0.22 0.99 ± 0.78
Pparg 0.67 ± 0.50 0.60 ± 0.21 0.75 ± 0.19 0.61 ± 0.20 1.01 ± 0.02 1.16 ± 0.01*
Cebpa 0.80 ± 0.60 0.74 ± 0.31 1.07 ± 0.64 0.93 ± 0.41 1.03 ± 0.04 0.89 ± 0.04*
Lipolysis
Pnpla2 1.12 ± 1.19 0.86 ± 0.58 0.40 ± 0.60 0.31 ± 0.45 1.01 ± 0.01 0.99 ± 0.02
Lipogenesis
Srebf1 0.80 ± 0.55 0.69 ± 0.37 0.87 ± 0.31 0.84 ± 0.23 0.92 ± 0.11 0.70 ± 0.14
Acaca 1.55 ± 2.04 1.39 ± 0.73 0.98 ± 0.53 0.99 ± 0.44 0.79 ± 0.29 0.96 ± 0.44
Fasn 0.65 ± 0.51 0.75 ± 0.38 0.97 ± 0.67 0.84 ± 0.43 0.76 ± 0.34 0.61 ± 0.12
Fabp4 1.11 ± 0.86 1.05 ± 0.40 4.18 ± 3.68 3.16 ± 3.03 0.99 ± 0.01 0.72 ± 0.16
Adipokines
Lep 1.54 ± 2.38 0.58 ± 0.49 1.23 ± 0.76 1.17 ± 0.80 0.67 ± 0.47 1.25 ± 0.78
Adipoq 0.84 ± 0.77 0.66 ± 0.31 0.72 ± 0.19 0.75 ± 0.16 1.02 ± 0.02 1.10 ± 0.08
Cfd 0.79 ± 0.79 0.72 ± 0.39 0.87 ± 0.32 0.83 ± 0.31 1.00 ± 0.005 0.91 ± 0.11
Browning
Cidea 2.91 ± 2.32 1.68 ± 0.75 1.06 ± 1.38 0.13 ± 0.12* 0.92 ± 0.12 0.94 ± 0.07
Ppara 1.26 ± 0.69 0.96 ± 0.35 0.88 ± 0.63 0.46 ± 0.28 0.98 ± 0.03 0.98 ± 0.21
Ucp1 N/A N/A N/A N/A 1.13 ± 0.18 0.70 ± 0.13*
Insulin signaling
Slc2a4 0.89 ± 0.94 0.62 ± 0.35 0.89 ± 0.57 0.64 ± 0.28 0.82 ± 0.25 0.72 ± 0.06
Insr 0.62 ± 0.43 0.56 ± 0.35 0.76 ± 0.37 0.84 ± 0.36 1.09 ± 0.13 0.90 ± 0.09
Irs1 1.00 ± 0.93 0.87 ± 0.51 1.10 ± 0.34 1.07 ± 0.39 1.54 ± 0.76 1.98 ± 0.73
Fibrosis
Fn1 0.45 ± 0.38 0.71 ± 0.33 1.40 ± 0.79 1.86 ± 0.82 1.03 ± 0.04 1.40 ± 0.32
Cola1a1 0.26 ± 0.38 0.19 ± 0.10 1.31 ± 0.78 1.68 ± 0.94 1.11 ± 0.16 1.98 ± 0.11†
Cola4a1 0.62 ± 0.52 0.54 ± 0.25 1.00 ± 0.32 1.23 ± 0.50 0.99 ± 0.01 1.08 ± 0.36
Cola6a1 0.61 ± 2.12 1.46 ± 1.15 1.80 ± 1.71 2.41 ± 2.04 1.18 ± 0.26 1.50 ± 0.49
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Figure 5.  AT phenotype and inflammation in 5-month-old WT and Lgals3−/− mice. Quantification of size, 
number, density and size distribution of adipocytes from VAT (a); adipocyte size from SAT (b); serum levels 
of leptin and adiponectin (c); qRT-PCR analysis of the inflammatory markers Tnfa, Il1b, Il6, and Ccl2 in SAT 
and VAT (d); representative immunohistochemical staining for F4/80 (original magnification, 400X; black 
arrows = macrophages), measurement of F4/80 positive cell number, and RT-PCR analysis of the macrophage 
marker Cd68 in VAT (e) in WT and Lgals3−/− mice. Values represent the mean ± SD (n = 6 per genotype). White 
bars = WT mice; black bars = Lgals3−/− mice; *P < 0.05, **P < 0.01 or ***P < 0.001 versus WT.
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Figure 6.  Tissue and systemic insulin sensitivity and glucose homeostasis in 5-month-old WT and Lgals3−/− mice. 
Representative Western blot analysis of phospho-AKT (p-AKT, 60 kDa) and total AKT (AKT, 60 kDa) in protein extracts 
from VAT cultures stimulated with insulin and quantification of phospho-AKT (active AKT) relative to total AKT (n = 4 
per genotype) (a); measurement of glucose uptake in ex vivo cultures of VAT (b) and skeletal muscle (c) treated with insulin 
(1 µM) and 2-deoxy-D-glucose (1 mM) (n = 4 per genotype); fasting glucose levels (n = 4 per genotype) (d); IPGTT (n = 5 
per genotype) (e); fasting insulin levels (f); HOMA-%β (g) (n = 6 per genotype); and euglycemic-hyperinsulinemic clamp 
(n = 7 per genotype) (h) in WT and Lgals3−/− mice. Values represent the mean ± SD. White bars and squares, continuous 
line = WT mice; black bars and triangles, dashed line = Lgals3−/− mice; *P < 0.05, **P < 0.01 or ***P < 0.001 versus WT.
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resolution of inflammation, and restoration of insulin sensitivity, older Lgals3−/− mice showed persistently abnor-
mal glucose metabolism associated with reduced insulin levels and HOMA-%B, suggesting that Lgals3 ablation 
might impair also β-cell functional reserve during aging.
Overall our data indicate that the concept of adiposopathy should be extended to normal feeding conditions, 
under which an AT dysfunction due to a defect of terminal adipogenesis may directly cause inflammation and IR 
at the tissue and systemic level, without inducing adipocyte degeneration/death and fat diversion to ectopic sites, 
consistent with the unchanged total fat mass. Conversely, in response to a high-fat intake, such an adipogenic 
defect may lower the threshold of critical volume beyond which adipocyte injury, fat diversion, and the detri-
mental downstream events  occur9. This concept is consistent with the increased susceptibility of Lgals3−/− mice 
to IR, inflammation, and diabetes induced by a high-fat  diet18,19.
The results of our study have important clinical implications, as they suggest that a genetic background that 
is associated with an impaired ability of pre-adipocytes to terminal differentiate into functional mature cells 
without affecting pre-adipocyte recruitment may underlie an increased susceptibility to develop abnormalities 
of insulin sensitivity and glucose regulation. Consistently, a growing body of evidence from human and experi-
mental obesity indicates that adiposopathy is mainly characterized by a defect in the hypertrophic response of 
newly formed adipocytes rather than by an impaired recruitment and proliferation of adipocyte  precursors32–36.
Our results may reconcile the apparently discordant findings of defective adipogenesis, unchanged body 
weight, and impaired glucose regulation previously reported in Lgals3−/− mice fed a standard  diet17–19. Never-
theless, there are some differences with previous studies using this mouse model, which however were also in 
contrast between each other for several  findings17–20.
The main strength of our work is the use of the Lgals3−/− mouse model, which is characterized by both 
impaired adipocyte differentiation and altered glucose regulation and is therefore suited to test the study hypoth-
esis. A weakness is the use of total body instead of AT-specific Lgals3−/− mice, which did not allow to rule out 
a background effect of whole-body deletion of Lgals3 especially on inflammation, which is modulated by this 
 lectin13,14, but also on IR and glucose homeostasis. Indeed, as discussed above, the persistence of altered glucose 
regulation despite AT maturation in 5-month-old Lgals3−/− mice might suggest that Lgals3 ablation directly affects 
the β-cell. However, the strict temporal relationship between AT maturation and function and systemic IR and 
inflammation, with all these changes being observed at 2 months and no longer detected at 5 months of age, 
strongly support a major role for Lgals3 deficiency at the AT level in the pathogenesis of metabolic derangement. 
Other limitations include the lack of mechanistic studies explaining the delayed AT maturation and the pan-
creatic defect observed in Lgals3−/− mice, which require further studies. However, unrevealing the mechanisms 
underlying the effect of Lgals3 ablation on AT and other metabolic organs was beyond the scope of our work.
In conclusion, our data indicate that Lgas3 deletion results in impaired terminal differentiation (maturation) 
of pre-adipocytes, which might directly affect insulin sensitivity and increase susceptibility to type 2 diabetes in 
the absence of an increased demand for fat storage and, hence, independently of increased fat accumulation and 
redistribution. This implies that defective adipogenesis is a central mechanism underlying IR and susceptibility 
to diabetes, thus providing the conceptual framework for designing and testing new molecules targeting AT 
adipogenic capacity.
Methods
Design. The study protocol was approved by the National Ethics Committee for Animal Experimentation of 
the Italian Minister of Health (D.lgs. 26/2014, Act n. 184) and included in vitro, in vivo, and ex vivo studies using 
5-week-old female Lgals3−/− and the corresponding C57BL/6J WT mice (gift of Daniel K Hsu & Fu-Tong Liu, 
Department of Dermatology, University of California-Davis, Sacramento, CA, USA).
In vitro studies. The SVF cells were isolated from SAT of WT and Lgals3−/− mice. Briefly, tissue was washed 
with PBS, mechanically disrupted, and enzymatically digested in a buffer containing 1.5  mg/ml collagenase 
type II, 0.5% BSA, and 15 mM HEPES (Merck KGaA, Darmstadt, Germany) for 45 min at 37 °C and 150 rpm. 
The disassociated tissue was filtered and centrifuged at 700 × g for 10 min to pellet SVF cells, which were then 
plated in DMEM/F12 supplemented with 10% FBS and 1% penicillin/streptomycin (Thermo Fisher Scientific, 
Waltham, MA, USA).
For Lgals3 knockdown experiments in mature adipocytes, murine 3T3-L1 pre-adipocytes (ATCC, Manassas, 
VA, USA) were induced to differentiate into fully mature adipocytes as per vendor’s protocol. At day 7 post-
induction, adipocytes were reverse transfected using Silencer Select siRNA to Lgals3 and irrelevant scrambled 
siRNA as control (Thermo Fisher Scientific) at day 7 post-induction using DharmaFECT Duo Transfection 
Reagent (Healthcare Dharmacon Inc., Lafayette, CO, USA).
In vivo studies. The animals were housed in single cages in a germ-free stabularium and cared according to the 
“Animal Research: Reporting of In  Vivo Experiments” (ARRIVE) guidelines (https ://www.nc3rs .org.uk/arriv 
e-guide lines ) and national laws and regulations. Mice received water and food ad  libitum. Body weights and 
fasting plasma glucose levels were measured monthly, together with food intake.
Part of the mice were subjected to an IPGTT (n = 6 per age and genotype) or a euglycemic-hyperinsulinemic 
clamp (n = 7 per age and genotype). The remaining mice (n = 6 per age and genotype) were starved for 4 h, then 
blood samples were collected, the animals were euthanized by cervical dislocation, and inguinal SAT, gonadal 
VAT, and interscapular BAT were sampled, weighed, and fixed in phosphate buffered 4% formaldehyde solution 
and processed for morphometric and immunohistochemical analysis or frozen in liquid nitrogen and stored at 
− 80 °C until analysis of gene expression by qRT-PCR.
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Ex vivo studies. Samples of VAT and gastrocnemius muscle were obtained from 4 mice per age and genotype, 
washed in PBS, and cultured for 2 h in RPMI containing penicillin and streptomycin (Thermo Fisher Scientific). 
Then, tissues were stimulated with 1 µM insulin (Merck KGaA) or vehicle for 20 min and processed for the 
assessment of glucose uptake or, in case of VAT, frozen and stored at − 80 °C for Western blot analysis.
Measurements. Adipogenic differentiation. The SVF cells were cultured for 14 days in complete DMEM/
F12 medium (Thermo Fisher Scientific) supplemented with 50  μM indomethacine, 0.5  μM hydrocortisone, 
0.5 mM isobutylmethylxanthine, and 5 μg/ml insulin (Merck KGaA).
Lipid accumulation was detected using Oil-Red-O staining (O0625, Sigma-Aldrich, St.Louis, MO, USA) with 
the aid of the image analysis system Optimas 6.5 (Bioscan, Washington DC, USA).
Cell proliferation was assessed by measuring BrdU incorporation using an Eloisa kit from Cell Biolabs (San 
Diego, CA, USA) following the manufacturer’s instructions.
Biochemistry and ELISA. Fasting blood samples were analyzed for glucose by an automated colorimetric 
instrument (Glucocard SM, Menarini, Florence, Italy) and insulin by ELISA (Ultrasensitive Mouse Insulin 
ELISA kit, Mercodia AB, Uppsala, Sweden); the HOMA-IR and HOMA-%β indexes were then calculated from 
glucose and insulin.
Levels of NEFAs were measured with a colorimetric Kit (MAK044, Merck KGaA). Serum levels of TNF-α, 
IL-1β, IL-6, leptin, and adiponectin were assessed using ELISA kits from R&D Systems (Minneapolis, MN, USA) 
and ENZO Life Sciences (Farmingdale, NY, USA) for leptin.
Histology, morphometry and Immunohistochemistry. Sections of VAT and SAT were stained with hematoxylin–
eosin for histological examination. Adipocyte size in VAT and SAT was evaluated by computer assisted image 
analysis (Optimas 6.5) on five serial sections viewed at 100X using a DIALUX 20EB Microscope (Leitz, Wetzlar, 
Germany) and a Pro-Series High performance CCD Camera (Immagini e Computer, Milan, Italy). Ten random 
fields of 0.78  mm2 per section, automatically selected by means of a step motor, were analyzed. Data were first 
averaged per section and then per animal.
The number of infiltrating macrophages was measured in five AT sections immunolabelled for the murine 
macrophage marker F4/80; twenty random, automatically selected 0.125 mm2 fields per section were analyzed. 
Perilipin-1 immunostaining was performed to identify dead/dying adipocytes in areas of accumulation of F4/80 
positive cells. The antibodies used for F4/80 and perilipin-1 immunohistochemistry are reported in Supplemen-
tary Table 1.
RNA isolation and qRT‑PCR. Total RNA was extracted from SAT and VAT using an RNA purification kit 
(QIAGEN, Hilden, Germany) and from BAT and cell cultures using TRIzol Reagent (Thermo Fisher Scientific).
qRT-PCR was carried out in 20 µl reactions using a StepOne RT-PCR instrument (Applied Biosystems, 
Monza, Italy)37. The expression of the following genes was assessed using the TaqMan Gene Expression Assays 
(Applied Biosystems) reported in Supplementary Table 2: Lgals3; the pre-adipocyte marker and adipogenesis 
inhibitor Dlk1; the adipogenic transcription factors Cebpa, Cebpb and Pparg; the lipolytic enzyme Pnpla2; the 
lipogenic factors Srebf1, Acaca, Fasn, and Fabp4; the adipokines Lep, Adipoq, and Cfd; the markers of browning 
Cidea, Ppara and, in BAT, Ucp1; the cell cycle regulator Ccnd1; the insulin signaling mediators Insulin Recep-
tor (Irs1), Irs1, and Slc2a4; the inflammatory cytokines Tnfa, Il1b, Il6, and Ccl2; the macrophage marker Cd68; 
the ER stress markers Hspa5, Ddit3, and Xbp1; and the fibrosis markers Fn1, Cola1a1, Cola4a1, and Cola6a1. 
Amplifications were normalized to the β-actin gene (Actb) and quantitation was performed using the ΔΔCT 
calculation, where results were expressed as arbitrary units or fold of control mean (WT mouse and untreated 
WT cells) to control for unwanted sources of variation.
Euglycemic‑hyperinsulinemic clamp and IPGTT . For euglycemic-hyperinsulinemic  clamp38,39, mice under-
went surgery for the positioning of catheters. Three-to-five days later, after a 6-h fast, a primed continuous 
(18.0 mU·kg-1·min-1) infusion of human insulin (Actrapid, Novo Nordisk, Copenhagen, Denmark) was started 
simultaneously with a variable infusion of 20% dextrose to maintain glucose concentration at 80–100 mg dL-1. 
Blood samples were taken at time 0 and at 10-min intervals thereafter for at least 2 h to measure glucose concen-
tration and adjust dextrose infusion rates. Insulin sensitivity (rate of peripheral glucose uptake [mg·kg-1·min-1]) 
was calculated from average glucose concentrations and dextrose infusion rates during the last 30 min of the 
steady-state clamp period.
For IPGTT, after a 6-h fast, blood was drawn to measure glucose levels before and 15, 30, 60, and 120 min 
after intraperitoneal injection of 1 g glucose per kg body weight (Merck KGaA).
Glucose uptake. Glucose uptake was assessed in insulin- or vehicle-stimulated VAT and gastrocnemius sam-
ples using the Glucose Uptake Colorimetric Assay Kit (MAK083, Merck KGaA), following the manufacturer’s 
instructions.
Western blot analysis. VAT samples stimulated with insulin or vehicle were homogenized in RIPA buffer sup-
plemented with protease and phosphatase inhibitors.
Total and phosphorylated Akt protein levels were assessed by Western blot  analysis40 using the antibodies 
reported in Supplementary Table 1. The protein bands were detected and analyzed by using the ChemiDoc 
XRS + System with Image Lab image acquisition and analysis software included (Bio-Rad laboratories, Hercules, 
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CA, USA). Results were normalized using the Stain-Free technology (Bio-Rad laboratories) and Akt phospho-
rylation was expressed as phosphorylated:total Akt ratio.
Statistical analysis. Results were expressed as means ± SD. Statistical significance was evaluated by Stu-
dent’s t test or the corresponding Mann–Whitney U test, for nonparametric variables.
A P-value < 0.05 was considered significant. All statistical tests were performed on raw data.
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